Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus MEGACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus MEGACE.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs MEGACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Category D/X
Category C
Progestin + Estrogen
Progestin